Phase I, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers
The purpose of this phase I study is to evaluate the safety and feasibility of CUE-102 in HLA-A*0201 positive patients with WT1 positive recurrent/ metastatic solid tumors, including pancreatic cancer.
Study ID: CUE-102-01
Trial Phase: Phase I
Trial Sponsor: Cue Biopharma
Therapies Used in This Trial: CUE-102